Actinogen XanaMIA ACW0009

Back to Drug Development Trials
Drug Development Trials

About the trial

Xanamem is a highly selective small molecule inhibitor of the enzyme (11β-HSD1), which increases the level of the hormone cortisol in the body. Xanamem is expected to decrease cortisol levels in brain cells by inhibiting this enzyme and consequently slow down the progression of Alzheimer’s disease.

View study

Who can be involved:

• Male or female, aged 50 years or older
• Must be diagnosed with MCI or mild Alzheimer’s disease
• Has an identified, reliable, study partner
• If using medications to treat symptoms related to Alzheimer’s disease, doses must be stable for at least 3 months prior to screening

What is involved:

• Week 1, 2, 4, 8, 12, 16, 20, 24, 36, safety follow-up (10 site visits) + 2 telephone call visits
• 9-month trial duration
• Oral tablet once a day
• 50% chance of receiving a placebo

Additional info:

For further information please contact Paula Mather, Clinical Trial Coordinator on Ph: 08 9389 6433 or Email: aarfctd@alzheimersresearch.org.au

* Please note that participants in this study may have a chance of being placed on a placebo medication.